APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pulmonary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174029950322 December 2025199 pages

Choose your research edition.

Industry ResearchPulmonary Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Pulmonary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Pulmonary Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Drugs include Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, GlaxoSmithKline Plc., Glenmark Pharmaceuticals Ltd., AbbVie Inc., AstraZeneca Plc., Zambon Company S.p.A and Wellona Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Pulmonary Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Pulmonary Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.

Sanofi SA

Novartis AG

GlaxoSmithKline Plc.

Glenmark Pharmaceuticals Ltd.

AbbVie Inc.

AstraZeneca Plc.

Zambon Company S.p.A

Wellona Pharma

Vertex Pharmaceuticals Inc.

Sumitomo Pharma Co. Ltd.

Merck Sharp & Dohme Limited

Medisol Lifescience Pvt. Ltd.

Meda Pharmaceuticals

Mallinckrodt Pharmaceuticals Plc.

Lupin Ltd.

Grifols, S.A.

F. Hoffmann La Roche Ltd.

Circassia Pharmaceuticals Plc.

Cipla Ltd.

Cheisi Farmaceutici S.p.A

Celon Pharma SA

Boehringer Ingelheim

Aurobindo Pharma Ltd.

Alaxia SAS

Aerogen Pharma Ltd.

Abbott Laboratories

Pulmonary Drugs Segment by Type

Antihistamines

Inhaled Corticosteroids

Vasodilators

Long Acting Beta-2 Agonists

Others

Pulmonary Drugs Segment by Application

Asthma & COPD

Cystic Fibrosis

Pulmonary Arterial Hypertension

Allergic Rhinitis

Others

Pulmonary Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Pulmonary Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Drugs industry.

Chapter 3: Detailed analysis of Pulmonary Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Antihistamines Table 3. Key Players of Inhaled Corticosteroids Table 4. Key Players of Vasodilators Table 3. Key Players of Long Acting Beta-2 Agonists Table 4. Key Players of Others Table 5. Global Pulmonary Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Asthma & COPD Table 7. Key Players of Cystic Fibrosis Table 8. Key Players of Pulmonary Arterial Hypertension Table 9. Key Players of Allergic Rhinitis Table 10. Key Players of Others Table 11. Global Pulmonary Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Pulmonary Drugs Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Pulmonary Drugs Market Share by Region (2021-2026) Table 14. Global Pulmonary Drugs Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Pulmonary Drugs Market Share by Region (2027-2032) Table 16. Pulmonary Drugs Industry Trends Table 17. Pulmonary Drugs Industry Drivers Table 18. Pulmonary Drugs Industry Opportunities and Challenges Table 19. Pulmonary Drugs Industry Restraints Table 20. Global Pulmonary Drugs Revenue by Company (US$ Million) & (2021-2026) Table 21. Global Pulmonary Drugs Revenue Market Share by Company (2021-2026) Table 22. Global Pulmonary Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 23. Global Pulmonary Drugs Key Company Head Office and Area Served Table 24. Global Pulmonary Drugs Company, Product Type & Application Table 25. Global Pulmonary Drugs Company Establishment Date Table 26. Global Company Market Concentration Ratio (CR5 and HHI) Table 27. Global Pulmonary Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 28. Global Pulmonary Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 30. Global Pulmonary Drugs Market Size by Type (2027-2032) & (US$ Million) Table 31. Global Pulmonary Drugs Revenue Market Share by Type (2021-2026) Table 32. Global Pulmonary Drugs Revenue Market Share by Type (2027-2032) Table 33. Global Pulmonary Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 35. Global Pulmonary Drugs Market Size by Application (2027-2032) & (US$ Million) Table 36. Global Pulmonary Drugs Revenue Market Share by Application (2021-2026) Table 37. Global Pulmonary Drugs Revenue Market Share by Application (2027-2032) Table 38. Teva Pharmaceutical Industries Ltd. Company Information Table 39. Teva Pharmaceutical Industries Ltd. Business Overview Table 40. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio Table 42. Teva Pharmaceutical Industries Ltd. Recent Development Table 43. Sanofi SA Company Information Table 44. Sanofi SA Business Overview Table 45. Sanofi SA Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Sanofi SA Pulmonary Drugs Product Portfolio Table 47. Sanofi SA Recent Development Table 48. Novartis AG Company Information Table 49. Novartis AG Business Overview Table 50. Novartis AG Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Novartis AG Pulmonary Drugs Product Portfolio Table 52. Novartis AG Recent Development Table 53. GlaxoSmithKline Plc. Company Information Table 54. GlaxoSmithKline Plc. Business Overview Table 55. GlaxoSmithKline Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio Table 57. GlaxoSmithKline Plc. Recent Development Table 58. Glenmark Pharmaceuticals Ltd. Company Information Table 59. Glenmark Pharmaceuticals Ltd. Business Overview Table 60. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio Table 62. Glenmark Pharmaceuticals Ltd. Recent Development Table 63. AbbVie Inc. Company Information Table 64. AbbVie Inc. Business Overview Table 65. AbbVie Inc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. AbbVie Inc. Pulmonary Drugs Product Portfolio Table 67. AbbVie Inc. Recent Development Table 68. AstraZeneca Plc. Company Information Table 69. AstraZeneca Plc. Business Overview Table 70. AstraZeneca Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. AstraZeneca Plc. Pulmonary Drugs Product Portfolio Table 72. AstraZeneca Plc. Recent Development Table 73. Zambon Company S.p.A Company Information Table 74. Zambon Company S.p.A Business Overview Table 75. Zambon Company S.p.A Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Zambon Company S.p.A Pulmonary Drugs Product Portfolio Table 77. Zambon Company S.p.A Recent Development Table 78. Wellona Pharma Company Information Table 79. Wellona Pharma Business Overview Table 80. Wellona Pharma Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Wellona Pharma Pulmonary Drugs Product Portfolio Table 82. Wellona Pharma Recent Development Table 83. Vertex Pharmaceuticals Inc. Company Information Table 84. Vertex Pharmaceuticals Inc. Business Overview Table 85. Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio Table 87. Vertex Pharmaceuticals Inc. Recent Development Table 88. Sumitomo Pharma Co. Ltd. Company Information Table 89. Sumitomo Pharma Co. Ltd. Business Overview Table 90. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 91. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio Table 92. Sumitomo Pharma Co. Ltd. Recent Development Table 93. Merck Sharp & Dohme Limited Company Information Table 94. Merck Sharp & Dohme Limited Business Overview Table 95. Merck Sharp & Dohme Limited Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 96. Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio Table 97. Merck Sharp & Dohme Limited Recent Development Table 98. Medisol Lifescience Pvt. Ltd. Company Information Table 99. Medisol Lifescience Pvt. Ltd. Business Overview Table 100. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 101. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio Table 102. Medisol Lifescience Pvt. Ltd. Recent Development Table 103. Meda Pharmaceuticals Company Information Table 104. Meda Pharmaceuticals Business Overview Table 105. Meda Pharmaceuticals Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 106. Meda Pharmaceuticals Pulmonary Drugs Product Portfolio Table 107. Meda Pharmaceuticals Recent Development Table 108. Mallinckrodt Pharmaceuticals Plc. Company Information Table 109. Mallinckrodt Pharmaceuticals Plc. Business Overview Table 110. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 111. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 112. Mallinckrodt Pharmaceuticals Plc. Recent Development Table 113. Lupin Ltd. Company Information Table 114. Lupin Ltd. Business Overview Table 115. Lupin Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 116. Lupin Ltd. Pulmonary Drugs Product Portfolio Table 117. Lupin Ltd. Recent Development Table 118. Grifols, S.A. Company Information Table 119. Grifols, S.A. Business Overview Table 120. Grifols, S.A. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 121. Grifols, S.A. Pulmonary Drugs Product Portfolio Table 122. Grifols, S.A. Recent Development Table 123. F. Hoffmann La Roche Ltd. Company Information Table 124. F. Hoffmann La Roche Ltd. Business Overview Table 125. F. Hoffmann La Roche Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 126. F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio Table 127. F. Hoffmann La Roche Ltd. Recent Development Table 128. Circassia Pharmaceuticals Plc. Company Information Table 129. Circassia Pharmaceuticals Plc. Business Overview Table 130. Circassia Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 131. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 132. Circassia Pharmaceuticals Plc. Recent Development Table 133. Cipla Ltd. Company Information Table 134. Cipla Ltd. Business Overview Table 135. Cipla Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 136. Cipla Ltd. Pulmonary Drugs Product Portfolio Table 137. Cipla Ltd. Recent Development Table 138. Cheisi Farmaceutici S.p.A Company Information Table 139. Cheisi Farmaceutici S.p.A Business Overview Table 140. Cheisi Farmaceutici S.p.A Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 141. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio Table 142. Cheisi Farmaceutici S.p.A Recent Development Table 143. Celon Pharma SA Company Information Table 144. Celon Pharma SA Business Overview Table 145. Celon Pharma SA Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 146. Celon Pharma SA Pulmonary Drugs Product Portfolio Table 147. Celon Pharma SA Recent Development Table 148. Boehringer Ingelheim Company Information Table 149. Boehringer Ingelheim Business Overview Table 150. Boehringer Ingelheim Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 151. Boehringer Ingelheim Pulmonary Drugs Product Portfolio Table 152. Boehringer Ingelheim Recent Development Table 153. Aurobindo Pharma Ltd. Company Information Table 154. Aurobindo Pharma Ltd. Business Overview Table 155. Aurobindo Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 156. Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio Table 157. Aurobindo Pharma Ltd. Recent Development Table 158. Alaxia SAS Company Information Table 159. Alaxia SAS Business Overview Table 160. Alaxia SAS Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 161. Alaxia SAS Pulmonary Drugs Product Portfolio Table 162. Alaxia SAS Recent Development Table 163. Aerogen Pharma Ltd. Company Information Table 164. Aerogen Pharma Ltd. Business Overview Table 165. Aerogen Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 166. Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio Table 167. Aerogen Pharma Ltd. Recent Development Table 168. Abbott Laboratories Company Information Table 169. Abbott Laboratories Business Overview Table 170. Abbott Laboratories Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 171. Abbott Laboratories Pulmonary Drugs Product Portfolio Table 172. Abbott Laboratories Recent Development Table 173. North America Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 174. North America Pulmonary Drugs Market Size by Type (2027-2032) & (US$ Million) Table 175. North America Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 176. North America Pulmonary Drugs Market Size by Application (2027-2032) & (US$ Million) Table 177. North America Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. North America Pulmonary Drugs Market Size by Country (2021-2026) Table 179. North America Pulmonary Drugs Market Size by Country (2027-2032) Table 180. Europe Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 181. Europe Pulmonary Drugs Market Size by Type (2027-2032) & (US$ Million) Table 182. Europe Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 183. Europe Pulmonary Drugs Market Size by Application (2027-2032) & (US$ Million) Table 184. Europe Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Europe Pulmonary Drugs Market Size by Country (2021-2026) Table 186. Europe Pulmonary Drugs Market Size by Country (2027-2032) Table 187. China Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 188. China Pulmonary Drugs Market Size by Type (2027-2032) & (US$ Million) Table 189. China Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 190. China Pulmonary Drugs Market Size by Application (2027-2032) & (US$ Million) Table 191. Asia Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 192. Asia Pulmonary Drugs Market Size by Type (2027-2032) & (US$ Million) Table 193. Asia Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 194. Asia Pulmonary Drugs Market Size by Application (2027-2032) & (US$ Million) Table 195. Asia Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 196. Asia Pulmonary Drugs Market Size by Country (2021-2026) Table 197. Asia Pulmonary Drugs Market Size by Country (2027-2032) Table 198. South America, Middle East & Africa Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 199. South America, Middle East & Africa Pulmonary Drugs Market Size by Type (2027-2032) & (US$ Million) Table 200. South America, Middle East & Africa Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 201. South America, Middle East & Africa Pulmonary Drugs Market Size by Application (2027-2032) & (US$ Million) Table 202. South America, Middle East & Africa Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 203. South America, Middle East & Africa Pulmonary Drugs Market Size by Country (2021-2026) Table 204. South America, Middle East & Africa Pulmonary Drugs Market Size by Country (2027-2032) Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Pulmonary Drugs Product Image Figure 2. Global Pulmonary Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Pulmonary Drugs Market Share by Type: 2025 VS 2032 Figure 4. Antihistamines Image Figure 5. Inhaled Corticosteroids Image Figure 6. Vasodilators Image Figure 7. Long Acting Beta-2 Agonists Image Figure 8. Others Image Figure 9. Global Pulmonary Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Pulmonary Drugs Market Share by Application: 2025 VS 2032 Figure 11. Asthma & COPD Image Figure 12. Cystic Fibrosis Image Figure 13. Pulmonary Arterial Hypertension Image Figure 14. Allergic Rhinitis Image Figure 15. Others Image Figure 16. Global Pulmonary Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 18. Global Pulmonary Drugs Market Share by Region: 2025 VS 2032 Figure 19. Years Considered Figure 20. Global Pulmonary Drugs Market Share by Players in 2025 Figure 21. Global Top 5 and 10 Pulmonary Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Pulmonary Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Pulmonary Drugs Revenue Market Share by Type (2021-2032) Figure 25. Global Pulmonary Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Pulmonary Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 28. North America Pulmonary Drugs Market Share by Type (2021-2032) Figure 29. North America Pulmonary Drugs Market Share by Application (2021-2032) Figure 30. North America Pulmonary Drugs Market Share by Country (2021-2032) Figure 31. United States Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 32. Canada Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 33. Mexico Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 34. Europe Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 35. Europe Pulmonary Drugs Market Share by Type (2021-2032) Figure 36. Europe Pulmonary Drugs Market Share by Application (2021-2032) Figure 37. Europe Pulmonary Drugs Market Share by Country (2021-2032) Figure 38. Germany Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 39. France Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 40. U.K. Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 41. Italy Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 42. Russia Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 43. Nordic Countries Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 44. China Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 45. China Pulmonary Drugs Market Share by Type (2021-2032) Figure 46. China Pulmonary Drugs Market Share by Application (2021-2032) Figure 47. Asia Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 48. Asia Pulmonary Drugs Market Share by Type (2021-2032) Figure 49. Asia Pulmonary Drugs Market Share by Application (2021-2032) Figure 50. Asia Pulmonary Drugs Market Share by Country (2021-2032) Figure 51. Japan Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 52. South Korea Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 53. Taiwan Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 54. Southeast Asia Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 55. India Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 56. Australia Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa Pulmonary Drugs Market Share by Type (2021-2032) Figure 59. South America, Middle East & Africa Pulmonary Drugs Market Share by Application (2021-2032) Figure 60. South America, Middle East & Africa Pulmonary Drugs Market Share by Country (2021-2032) Figure 61. Brazil Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 62. South Africa Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Saudi Arabia Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 64. Turkey Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Argentina Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 66. UAE Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 67. Egypt Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 68. Chile Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Antihistamines
  • Inhaled Corticosteroids
  • Vasodilators
  • Long Acting Beta-2 Agonists
  • Others
Applications
  • Asthma & COPD
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension
  • Allergic Rhinitis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Glenmark Pharmaceuticals Ltd.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Zambon Company S.p.A
  • Wellona Pharma
  • Vertex Pharmaceuticals Inc.
  • Sumitomo Pharma Co. Ltd.
  • Merck Sharp & Dohme Limited
  • Medisol Lifescience Pvt. Ltd.
  • Meda Pharmaceuticals
  • Mallinckrodt Pharmaceuticals Plc.
  • Lupin Ltd.
  • Grifols, S.A.
  • F. Hoffmann La Roche Ltd.
  • Circassia Pharmaceuticals Plc.
  • Cipla Ltd.
  • Cheisi Farmaceutici S.p.A
  • Celon Pharma SA
  • Boehringer Ingelheim
  • Aurobindo Pharma Ltd.
  • Alaxia SAS
  • Aerogen Pharma Ltd.
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Pulmonary Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Antihistamines
  5. 1.2.3 Inhaled Corticosteroids
  6. 1.2.4 Vasodilators
  7. 1.2.5 Long Acting Beta-2 Agonists
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Pulmonary Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Asthma & COPD
  12. 1.3.3 Cystic Fibrosis
  13. 1.3.4 Pulmonary Arterial Hypertension
  14. 1.3.5 Allergic Rhinitis
  15. 1.3.6 Others
  16. 1.4 Global Market Growth Prospects
  17. 1.5 Global Pulmonary Drugs Growth Trends by Region
  18. 1.5.1 Global Pulmonary Drugs Market Size by Region: 2021 VS 2025 VS 2032
  19. 1.5.2 Pulmonary Drugs Market Size by Region (2021-2026)
  20. 1.5.3 Pulmonary Drugs Market Size by Region (2027-2032)
  21. 1.6 Assumptions and Limitations
  22. 1.7 Study Goals and Objectives
  23. 1.8 Years Considered
2 Global Pulmonary Drugs Market Dynamics
  1. 2.1 Pulmonary Drugs Industry Trends
  2. 2.2 Pulmonary Drugs Industry Drivers
  3. 2.3 Pulmonary Drugs Industry Opportunities and Challenges
  4. 2.4 Pulmonary Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Pulmonary Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Pulmonary Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Pulmonary Drugs Key Company Head office and Area Served
  4. 3.4 Global Pulmonary Drugs Company, Product Type & Application
  5. 3.5 Global Pulmonary Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Pulmonary Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Pulmonary Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Pulmonary Drugs Tier 1, Tier 2, and Tier 3
4 Pulmonary Drugs Market by Type
  1. 4.1 Global Pulmonary Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Pulmonary Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Pulmonary Drugs Market Size Share by Type (2021-2032)
5 Pulmonary Drugs Market by Application
  1. 5.1 Global Pulmonary Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Pulmonary Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Pulmonary Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd.
  2. 6.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 6.2 Sanofi SA
  8. 6.2.1 Sanofi SA Company Information
  9. 6.2.2 Sanofi SA Business Overview
  10. 6.2.3 Sanofi SA Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Sanofi SA Pulmonary Drugs Product Portfolio
  12. 6.2.5 Sanofi SA Recent Developments
  13. 6.3 Novartis AG
  14. 6.3.1 Novartis AG Company Information
  15. 6.3.2 Novartis AG Business Overview
  16. 6.3.3 Novartis AG Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Novartis AG Pulmonary Drugs Product Portfolio
  18. 6.3.5 Novartis AG Recent Developments
  19. 6.4 GlaxoSmithKline Plc.
  20. 6.4.1 GlaxoSmithKline Plc. Company Information
  21. 6.4.2 GlaxoSmithKline Plc. Business Overview
  22. 6.4.3 GlaxoSmithKline Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio
  24. 6.4.5 GlaxoSmithKline Plc. Recent Developments
  25. 6.5 Glenmark Pharmaceuticals Ltd.
  26. 6.5.1 Glenmark Pharmaceuticals Ltd. Company Information
  27. 6.5.2 Glenmark Pharmaceuticals Ltd. Business Overview
  28. 6.5.3 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio
  30. 6.5.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  31. 6.6 AbbVie Inc.
  32. 6.6.1 AbbVie Inc. Company Information
  33. 6.6.2 AbbVie Inc. Business Overview
  34. 6.6.3 AbbVie Inc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 AbbVie Inc. Pulmonary Drugs Product Portfolio
  36. 6.6.5 AbbVie Inc. Recent Developments
  37. 6.7 AstraZeneca Plc.
  38. 6.7.1 AstraZeneca Plc. Company Information
  39. 6.7.2 AstraZeneca Plc. Business Overview
  40. 6.7.3 AstraZeneca Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 AstraZeneca Plc. Pulmonary Drugs Product Portfolio
  42. 6.7.5 AstraZeneca Plc. Recent Developments
  43. 6.8 Zambon Company S.p.A
  44. 6.8.1 Zambon Company S.p.A Company Information
  45. 6.8.2 Zambon Company S.p.A Business Overview
  46. 6.8.3 Zambon Company S.p.A Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Zambon Company S.p.A Pulmonary Drugs Product Portfolio
  48. 6.8.5 Zambon Company S.p.A Recent Developments
  49. 6.9 Wellona Pharma
  50. 6.9.1 Wellona Pharma Company Information
  51. 6.9.2 Wellona Pharma Business Overview
  52. 6.9.3 Wellona Pharma Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Wellona Pharma Pulmonary Drugs Product Portfolio
  54. 6.9.5 Wellona Pharma Recent Developments
  55. 6.10 Vertex Pharmaceuticals Inc.
  56. 6.10.1 Vertex Pharmaceuticals Inc. Company Information
  57. 6.10.2 Vertex Pharmaceuticals Inc. Business Overview
  58. 6.10.3 Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio
  60. 6.10.5 Vertex Pharmaceuticals Inc. Recent Developments
  61. 6.11 Sumitomo Pharma Co. Ltd.
  62. 6.11.1 Sumitomo Pharma Co. Ltd. Company Information
  63. 6.11.2 Sumitomo Pharma Co. Ltd. Business Overview
  64. 6.11.3 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio
  66. 6.11.5 Sumitomo Pharma Co. Ltd. Recent Developments
  67. 6.12 Merck Sharp & Dohme Limited
  68. 6.12.1 Merck Sharp & Dohme Limited Company Information
  69. 6.12.2 Merck Sharp & Dohme Limited Business Overview
  70. 6.12.3 Merck Sharp & Dohme Limited Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio
  72. 6.12.5 Merck Sharp & Dohme Limited Recent Developments
  73. 6.13 Medisol Lifescience Pvt. Ltd.
  74. 6.13.1 Medisol Lifescience Pvt. Ltd. Company Information
  75. 6.13.2 Medisol Lifescience Pvt. Ltd. Business Overview
  76. 6.13.3 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio
  78. 6.13.5 Medisol Lifescience Pvt. Ltd. Recent Developments
  79. 6.14 Meda Pharmaceuticals
  80. 6.14.1 Meda Pharmaceuticals Company Information
  81. 6.14.2 Meda Pharmaceuticals Business Overview
  82. 6.14.3 Meda Pharmaceuticals Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Meda Pharmaceuticals Pulmonary Drugs Product Portfolio
  84. 6.14.5 Meda Pharmaceuticals Recent Developments
  85. 6.15 Mallinckrodt Pharmaceuticals Plc.
  86. 6.15.1 Mallinckrodt Pharmaceuticals Plc. Company Information
  87. 6.15.2 Mallinckrodt Pharmaceuticals Plc. Business Overview
  88. 6.15.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  90. 6.15.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments
  91. 6.16 Lupin Ltd.
  92. 6.16.1 Lupin Ltd. Company Information
  93. 6.16.2 Lupin Ltd. Business Overview
  94. 6.16.3 Lupin Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Lupin Ltd. Pulmonary Drugs Product Portfolio
  96. 6.16.5 Lupin Ltd. Recent Developments
  97. 6.17 Grifols, S.A.
  98. 6.17.1 Grifols, S.A. Company Information
  99. 6.17.2 Grifols, S.A. Business Overview
  100. 6.17.3 Grifols, S.A. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Grifols, S.A. Pulmonary Drugs Product Portfolio
  102. 6.17.5 Grifols, S.A. Recent Developments
  103. 6.18 F. Hoffmann La Roche Ltd.
  104. 6.18.1 F. Hoffmann La Roche Ltd. Company Information
  105. 6.18.2 F. Hoffmann La Roche Ltd. Business Overview
  106. 6.18.3 F. Hoffmann La Roche Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio
  108. 6.18.5 F. Hoffmann La Roche Ltd. Recent Developments
  109. 6.19 Circassia Pharmaceuticals Plc.
  110. 6.19.1 Circassia Pharmaceuticals Plc. Company Information
  111. 6.19.2 Circassia Pharmaceuticals Plc. Business Overview
  112. 6.19.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  114. 6.19.5 Circassia Pharmaceuticals Plc. Recent Developments
  115. 6.20 Cipla Ltd.
  116. 6.20.1 Cipla Ltd. Company Information
  117. 6.20.2 Cipla Ltd. Business Overview
  118. 6.20.3 Cipla Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Cipla Ltd. Pulmonary Drugs Product Portfolio
  120. 6.20.5 Cipla Ltd. Recent Developments
  121. 6.21 Cheisi Farmaceutici S.p.A
  122. 6.21.1 Cheisi Farmaceutici S.p.A Company Information
  123. 6.21.2 Cheisi Farmaceutici S.p.A Business Overview
  124. 6.21.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio
  126. 6.21.5 Cheisi Farmaceutici S.p.A Recent Developments
  127. 6.22 Celon Pharma SA
  128. 6.22.1 Celon Pharma SA Company Information
  129. 6.22.2 Celon Pharma SA Business Overview
  130. 6.22.3 Celon Pharma SA Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 Celon Pharma SA Pulmonary Drugs Product Portfolio
  132. 6.22.5 Celon Pharma SA Recent Developments
  133. 6.23 Boehringer Ingelheim
  134. 6.23.1 Boehringer Ingelheim Company Information
  135. 6.23.2 Boehringer Ingelheim Business Overview
  136. 6.23.3 Boehringer Ingelheim Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  137. 6.23.4 Boehringer Ingelheim Pulmonary Drugs Product Portfolio
  138. 6.23.5 Boehringer Ingelheim Recent Developments
  139. 6.24 Aurobindo Pharma Ltd.
  140. 6.24.1 Aurobindo Pharma Ltd. Company Information
  141. 6.24.2 Aurobindo Pharma Ltd. Business Overview
  142. 6.24.3 Aurobindo Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  143. 6.24.4 Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio
  144. 6.24.5 Aurobindo Pharma Ltd. Recent Developments
  145. 6.25 Alaxia SAS
  146. 6.25.1 Alaxia SAS Company Information
  147. 6.25.2 Alaxia SAS Business Overview
  148. 6.25.3 Alaxia SAS Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  149. 6.25.4 Alaxia SAS Pulmonary Drugs Product Portfolio
  150. 6.25.5 Alaxia SAS Recent Developments
  151. 6.26 Aerogen Pharma Ltd.
  152. 6.26.1 Aerogen Pharma Ltd. Company Information
  153. 6.26.2 Aerogen Pharma Ltd. Business Overview
  154. 6.26.3 Aerogen Pharma Ltd. Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  155. 6.26.4 Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio
  156. 6.26.5 Aerogen Pharma Ltd. Recent Developments
  157. 6.27 Abbott Laboratories
  158. 6.27.1 Abbott Laboratories Company Information
  159. 6.27.2 Abbott Laboratories Business Overview
  160. 6.27.3 Abbott Laboratories Pulmonary Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  161. 6.27.4 Abbott Laboratories Pulmonary Drugs Product Portfolio
  162. 6.27.5 Abbott Laboratories Recent Developments
7 North America
  1. 7.1 North America Pulmonary Drugs Market Size (2021-2032)
  2. 7.2 North America Pulmonary Drugs Market Size by Type
  3. 7.2.1 North America Pulmonary Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Pulmonary Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Pulmonary Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Pulmonary Drugs Market Size by Application
  7. 7.3.1 North America Pulmonary Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Pulmonary Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Pulmonary Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Pulmonary Drugs Market Size by Country
  11. 7.4.1 North America Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Pulmonary Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Pulmonary Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Pulmonary Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Pulmonary Drugs Market Size (2021-2032)
  2. 8.2 Europe Pulmonary Drugs Market Size by Type
  3. 8.2.1 Europe Pulmonary Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Pulmonary Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Pulmonary Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Pulmonary Drugs Market Size by Application
  7. 8.3.1 Europe Pulmonary Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Pulmonary Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Pulmonary Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Pulmonary Drugs Market Size by Country
  11. 8.4.1 Europe Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Pulmonary Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Pulmonary Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Pulmonary Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Pulmonary Drugs Market Size (2021-2032)
  2. 9.2 China Pulmonary Drugs Market Size by Type
  3. 9.2.1 China Pulmonary Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Pulmonary Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Pulmonary Drugs Market Share by Type (2021-2032)
  6. 9.3 China Pulmonary Drugs Market Size by Application
  7. 9.3.1 China Pulmonary Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Pulmonary Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Pulmonary Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Pulmonary Drugs Market Size (2021-2032)
  2. 10.2 Asia Pulmonary Drugs Market Size by Type
  3. 10.2.1 Asia Pulmonary Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Pulmonary Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Pulmonary Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Pulmonary Drugs Market Size by Application
  7. 10.3.1 Asia Pulmonary Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Pulmonary Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Pulmonary Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Pulmonary Drugs Market Size by Country
  11. 10.4.1 Asia Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Pulmonary Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Pulmonary Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Pulmonary Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Pulmonary Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Pulmonary Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Pulmonary Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Pulmonary Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Pulmonary Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Pulmonary Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Pulmonary Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Pulmonary Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Pulmonary Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Pulmonary Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Pulmonary Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Pulmonary Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Pulmonary Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Pulmonary Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst